| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd6313cd852d966c754906912dc1fe4b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52 |
| filingDate |
2005-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc0c5ae1c4b66b3a5c39099e9b04932b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_377e5aa15dff271e71772f2bb17766d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7ed948789839528589cf908f74dac61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d4d0499bc5dae43b0b3658e70ae8577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff1530636baab368eb47d7e5cb60cef6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b84f3bc5a79cd3491e409dd3df35cda |
| publicationDate |
2009-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009311218-A1 |
| titleOfInvention |
mutant interferon alpha protein and use thereof |
| abstract |
The present invention has objects to provide a mutant interferon-α protein having a higher anti-viral and anti-tumor activity and to provide an agent for susceptive diseases, which contains the mutant interferon-α protein as an effective ingredient; and solves the above objects by providing a mutant protein which has an amino acid sequence of human interferon-α subtype α8 represented by any one of SEQ ID NOs:1 to 3, where the arginine residue at the 145 th has been replaced with leucine, isoleucine, or valine residue; the alanine residue at the 146 th has been replaced with asparagine or serine residue; and the methionine residue at the 149 th has been replaced with tyrosine residue; and an agent for susceptive diseases, containing the mutant protein. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104056254-A |
| priorityDate |
2004-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |